Podcasts about R21

Die aktuellen Automobilkurznachrichten mit Michael Weyland Thema heute:  Neuer Porsche 911 GT3 meistert Nordschleife in 6:56,294 Minuten      Der Porsche 911 GT3 ist das schnellste Serienfahrzeug mit manuellem Schaltgetriebe auf der Nürburgring Nordschleife. Porsche Markenbotschafter Jörg Bergmeister unterbot den bis dato geltenden Rekord eines deutlich stärker motorisierten Mitbewerbers um mehr als 9,5 Sekunden. Aufgrund umfangreicher Weiterentwicklungen aller performancerelevanten Fahrzeugkomponenten war der handgeschaltete 911 GT3 mit Weissach Paket sogar 3,633 Sekunden schneller unterwegs als das Vorgängermodell (992.1) mit Porsche Doppelkupplungsgetriebe (PDK).   „Immer mehr Kunden des 911 GT3 entscheiden sich für das Sechsgang-Schaltgetriebe. Und immer häufiger werden wir von diesen Kunden gefragt, wie schnell denn ein 911 GT3 mit Handschaltung auf der Nordschleife wäre“, berichtet man bei Porsche. „Diese Frage haben wir jetzt beantwortet und sind – obwohl wir wissen, dass die Variante mit PDK noch einmal deutlich schneller ist – unsere offizielle Rundenzeit mit manuellem Sechsganggetriebe gefahren. Auch ohne die automatisierten, superschnellen und präzisen Schaltvorgänge des PDK und mit konventionellem statt elektronisch geregeltem Sperrdifferenzial nimmt der neue 911 GT3 seinem Vorgänger mit PDK rund 3,6 Sekunden ab.“ Bei sonnigem Wetter, 12 Grad Umgebungs- und 27 Grad Asphalttemperatur ging Jörg Bergmeister am späten Nachmittag im 375 kW (510 PS) starken 911 GT3 mit Weissach Paket auf die 20,832 Kilometer lange Strecke. Wie bei der offiziellen Runde des Vorgängermodells waren straßenzugelassene Reifen des Typs Michelin Pilot Sport Cup2 R in den Dimensionen 255/35 R20 vorn und 315/30 R21 hinten montiert. Bessere Performance bei gleicher Motorleistung „Der neue 911 GT3 vermittelt am Limit noch mehr Vertrauen als das Vorgängermodell. Ich bin in fast jeder Kurve schneller unterwegs gewesen“, beschreibt Jörg Bergmeister das Fahrverhalten des Sportwagens. „Vor allem beim Fahrwerk haben wir eine Menge vom 911 GT3 RS gelernt. Das Auto liegt auf Bodenwellen und über die Curbs deutlich ruhiger. Und dank der acht Prozent kürzeren Übersetzung liegt bei gleicher Motorleistung beim Beschleunigen spürbar mehr Kraft an der Hinterachse an. Auch wenn es mit dem Siebengang-PDK noch ein paar Sekunden schneller gegangen wäre – mit dem Sechsgang-Schaltgetriebe hatte ich auf der schnellen Runde definitiv mehr zu tun und somit auch ein bisschen mehr Spaß“. Alle Fotos: Dr. Ing. h.c. F. Porsche AG   Diesen Beitrag können Sie nachhören oder downloaden unter:

From Tuesday, 1st April 2025, South Africans will see the implementation of the increased earnings threshold that will affect all employees earning more than R261,700 per year, which is around R21 800 per month. The earnings threshold impacts the application of provisions of the Basic Conditions of Employment Act, the Labour Relations Act and the Employment Equity Act. In terms of the new regulations, employees earning more than the earnings threshold are excluded from the provisions which regulate ordinary hours of work, overtime, Sunday pay, pay for night work and pay for work on public holidays among others. For more Bongiwe Zwane spoke to Malesela Letwaba, Associate in Employment Law at legal firm, Cliffe Dekker Hofmeyr - CDH...

Today on The Midday Report, host Mandy Wiener covers the latest news, including updates on EMPD’s illegal protest which caused havoc on Johannesburg’s roads. She also gives an update on the February inflation numbers released by Stats SA. Meanwhile, the Health Minister claims that the private sector has distanced itself from the fight against TB. Former South African Airways (SAA) board member Yakhe Kwinana faces allegations of extortion, intimidation and malicious property damage. The DA is back in court over the ANC’s cadre deployment policy. Listen live - The Midday Report with Mandy Wiener is broadcast on weekdays from noon to 1:00 pm on 702 and CapeTalk.See omnystudio.com/listener for privacy information.

This week, Jason Jarvis joins Aebhric O'Kelly on a deep dive into malaria, covering the lifecycle, symptoms, diagnostic tools, treatment options, and the latest vaccine developments. The discussion emphasises the importance of understanding malaria's complexities, the challenges in diagnosis and treatment, and the promising advancements in vaccine research to eradicate this deadly disease.TakeawaysParasitic protozoa transmitted by Anopheles mosquitoes cause malaria.The lifecycle of malaria involves complex stages in both mosquitoes and humans.Symptoms of malaria can vary significantly based on previous exposure to the disease.Severe malaria can lead to critical conditions like altered consciousness and hypoglycaemia.Rapid diagnostic tests (RDTs) are essential but not foolproof in detecting malaria.The R21 malaria vaccine shows promising efficacy and significantly advances malaria prevention.Public health efforts primarily focus on protecting vulnerable populations, especially children.Understanding the fever patterns can aid in diagnosing malaria and other diseases.Vaccination for adults is being researched, but current recommendations prioritise children.Staying informed through reputable sources like WHO and CDC is crucial for those travelling to malaria-endemic areas.Chapters00:00 Introduction to Malaria and Its Lifecycle14:58 Understanding Malaria Symptoms and Severity30:07 Diagnostic Tools and Treatment Options34:09 Vaccines: Current Developments and Future Prospects44:57 Resources for Further Learning

A couple of dead bodies still remain trapped under a bus which crashed and rolled on the R21 near O.R Tambo International Airport on Gauteng's East Rand. This has preliminary investigations continue to take place in order to understand what may have led to this fatal accident. At least 12 people have been confirmed to have died while 45 others have been seriously injured and taken to nearby hospitals. Gauteng traffic spokesperson, Sello Maremane says the cause of the accident remains unclear...

At 06:45 on Tuesday, Ekurhuleni Emergency Services received a report of a severe bus crash on the R21 heading OR Tambo International Airport. At least 12 people have died after the bus overturned at the R21/R24 split, causing major traffic delays and lane closures.

Infinite Inning 317: You Can't Be There If You're Already Here The show must go on, and so we begin with Dodgers Hall of Fame manager Walt Alston, the overreach of the man he replaced, Chuck Dressen (and Mrs. Dressen too) and what Walt did to make ends meet, then pause for some ruminations on The Way We Live Now, then visit Opening Day at Yankee Stadium in 1957 for home-run heroics by a forgotten player, bad play-by-play, and a dire song choice. Tigger Warning: There is a machine gun fired about 18 minutes into the episode. There is also one cussword at around the 20-minute mark. Cauterize your ears if necessary. (LightMachineGun2.wav by SuperPhat. 8bit-scream.wav by DeltaCode. R21-09-Man Screams.wav, R28-45-Woman Screams in Rumbling Space.wav by craigsmith. ) The Infinite Inning is not only about baseball but a state of mind. Steven Goldman discusses the game's present, past, and future with forays outside the foul lines to the culture at large. Expect stats, anecdotes, digressions, explorations of writing and fandom, and more Casey Stengel quotations than you thought possible. Along the way, they'll try to solve the puzzle that is the Infinite Inning: How do you find the joy in life when you can't get anybody out?

Key Timestamps:02:00 – Welcome to Wisdom & Wellness Season 7, Episode 2, featuring Pastor Koketso.05:02 – The significance of Pastor K's favorite phrase: “A kid from Kuruman helped by God.”06:26 – A look into Pastor K's childhood and upbringing.08:15 – What Pastor K's dream was before realizing there was more to dream about.09:34 – Beginning his ministry as a youth pastor—choosing R8,000 over R21,000.18:38 – The early days of Mmuso Church.22:43 – Losing money, setting aside ego, and moving in with in-laws while starting Mmuso Church.27:55 – Facing the scars of financial loss and finding meaning in the struggle.31:12 – Biblical order: The importance of discipline and following the right path.36:29 – A deep dive into self-control and its role in our lives.41:15 – The level of discipline and self-control needed to lead 2,000 people weekly.44:42 – The realization that early mentors seemed "above human level" and how this shaped his approach to fitness and leadership.46:44 – A moment where a lack of self-control led to anger.52:33 – The necessity of personal devotion in spiritual growth.56:40 – Gaining perspective from growing up without parents.59:57 – The process of grieving well and finding healing.01:03:46 – A life-changing lesson.01:04:41 – Wall of Wisdom – final reflections.Thank You for Tuning In!Visit our website for updates: Wisdom & Wellness - A Vibrant CommunityJoin our mailing list for exclusive news: Sign Up HereFollow us on Instagram: @wisdomwellness_

Les Archives départementales de l'Aude vous invitent à (re) découvrir l'affaire Borras telle que vous ne l'avez jamais entendue, mise en mots par Michel Moatti. Joseph Borras fut emprisonné à tort pour le meurtre des époux Pradiès en 1887, dans une ferme appelée le petit Condom, entre Narbonne et Cuxac-d'Aude. Michel Moatti est un écrivain et journaliste français, maître de conférences en sociologie à l'Université de Montpellier. Son travail porte sur l'opinion publique, les médias et la violence sur internet. Texte : Michel Moatti Voix : La narratrice : Dominique Porret La journaliste : Hélène Marty Théophile Marcou : Claude-Marie Robion Enregistrement et montage : Frédéric Pérès Recherches documentaires : Claire SCHARFFE et Frédéric Pérès Un projet coordonné par Occitanie Livre et Lecture et soutenu par l'appel à projet patrimoine écrit 2024 du ministère de la Culture . Crédits bruitages et musiques : Ambience : Night in nature (South of France) - 2 by SamuelGremaud -- https://freesound.org/s/436999/ -- License: Creative Commons 0 Knocking on Door 2 (Indoor/Mixed) by EvanBoyerman -- https://freesound.org/s/372231/ -- License: Attribution 3.0 Wooden Door Open3 by theshaggyfreak -- https://freesound.org/s/317529/ -- License: Attribution 4.0  Hammer on Wood by L.i.Z.e.L.l.E_+ -- https://freesound.org/s/707864/ -- License: Creative Commons 0 Cellule intérieur.wav by johntrap -- https://freesound.org/s/528288/ -- License: Creative Commons 0 R21-07-Men Yelling While Fighting.wav by craigsmith -- https://freesound.org/s/486193/ -- License: Creative Commons 0 woman scream.wav by starnezio -- https://freesound.org/s/609973/ -- License: Creative Commons 0 Bloody Stab 1 by MinecraftGamerLR -- https://freesound.org/s/728696/ -- License: Attribution 4.0 Man running downstairs in a house.wav by SirBlibofDoh -- https://freesound.org/s/664203/ -- License: Attribution NonCommercial 4.0 wood hammer, gavel, knock, pound, jury, court.mp3 by JohnsonBrandEditing -- https://freesound.org/s/173941/ -- License: Creative Commons 0 ssh (hush) by dividedby.one -- https://freesound.org/s/240381/ -- License: Creative Commons 0 Suspenseful Gloomy Crime by Nancy_Sinclair -- https://freesound.org/s/750227/ -- License: Creative Commons 0 Somber Atmosphere by Nancy_Sinclair -- https://freesound.org/s/750225/ -- License: Creative Commons 0 Tragic and Melancholic by Nancy_Sinclair -- https://freesound.org/s/750216/ -- License: Creative Commons 0 LS_34861-2_FR_Crowd_chatting_in_reverberant_hall by kevp888 -- https://freesound.org/s/716601/ -- License: Attribution 4.0 chut FR by w_ortiz -- https://freesound.org/s/709922/ -- License: Creative Commons 0 ssh (hush) by dividedby.one -- https://freesound.org/s/240381/ -- License: Creative Commons 0 Lenznbua Motorbike single 2.mp3 by lenznbua -- https://freesound.org/s/412437/ -- License: Creative Commons 0 Piano Solo 01 by BergsteinProd -- https://freesound.org/s/580657/ -- License: Attribution 3.0 "Breath of the Mountains" by Tristan Lohengrin www.tristanlohengrin.com

Immigration is a spotlight issue, especially heading into the next administration. Some say the United States is under attack—that the entrance of millions of immigrants, some of whom intend to and do cause harm to Americans, constitutes an “invasion” or "predatory incursion" of the sort mentioned in Article I of the Constitution and the Alien Enemies Act (AEA). Others contend, however, that allowing the term “invasion” or "predatory incursion" to apply to illegal immigration is both wrong and dangerous, and would allow for the possibility of states engaging in war or mounting hostility with neighboring countries. Is the US under invasion or predatory incursion by illegal immigrants? Can illegal immigration be an instrument to diminish the sovereignty of a nation? Join us in discussing these important questions and more.Featuring:Hon. Ken Cuccinelli, Former Acting Deputy Secretary for the Department of Homeland SecurityProf. Ilya Somin, Professor of Law, Antonin Scalia Law School, George Mason UniversityModerator: Joseph Humire, Executive Director, Center for a Secure Free Society--To register, click the link above.--For reference:Policy Brief: How States Can Secure the BorderAttorney General Opinion No. I22-001(R21-015) Immigration is Not InvasionCourts Might Not Stop Trump's Illicit Plans for Mass Deportations

Malaria, a preventable mosquito-borne disease, kills 600,000 people annually in Africa, most of them are children under five. Nigeria accounts for 30% of these deaths globally. This week, the country started administering the R21 malaria vaccine to children aged 5 to 11 months, beginning in Bayelsa and Kebbi states, which have high infection rates. Developed by Oxford University and manufactured in India, the vaccine has 75% efficacy. With 1 million doses donated by Gavi, the campaign is expected to expand nationwide by 2025. In today's episode Alan Kasujja speaks to the BBC's Health reporter Makuochi Okafor who was in Bayelsa this week and Professor Halidou Tinto, who helped to test the vaccine in Burkina Faso. Presenter: Alan Kasujja. Guests: Makouchi Okafor, Halidou Tinto

⁠⁠⁠Based. auf Patreon unterstützen.⁠⁠⁠ ⁠Patreon Folge mit Martin Hagen. Als bürgerliche Parteien gelten gemeinhin die FDP und die CDU. Aber auch die Grünen und die AfD sehen sich als bürgerlich. Keiner weiß also so recht, was das sein soll dieses "bürgerlich". Zum ersten Mal nehmen wir in unserem Studio in Berlin auf und fragen Martin Hagen, einen, der es wissen muss. Hagen ist nämlich nicht nur FDP-Vorsitzender in Bayern und sitzt im FDP, Bundesvorstand, sondern ist seit diesem Jahr auch noch Geschäftsführer der bürgerlichen Denkfabrik R21. Gegründet von einigen enttäuschten CDU-Mitgliedern im Jahr 2021 soll R21 ein Ort der Debatte für liberale und konservative Ideen sein. Doch haben diese beiden Weltanschauungen denn tatsächlich so viel gemeinsam? Diese Debatte lässt sich auch auf die Bundespolitik übertragen. Lange Zeit galt die FDP als der natürliche Regieurngspartner der CDU. Doch wie sinnvoll ist es, als Liberaler in einer anderen politischen Strömung ein Partner zu sehen? Macht man sich als kleinerer Partner damit langfristig zum Steigbügelhalter des Konservatismus? Wo gibt es Schnittstellen und wo sieht Hagen Konfliktpunkte? Außerdem, schauen wir gemeinsam auf die Außenwirkung von R21. Während die Süddeutsche Zeitung in der Denkfabrik eine “konservative Selbsthilfegruppe” sieht, schreibt die NZZ von “Kulturkämpfern für die bürgerliche Mitte”. Wie steht Martin Hagen zu dieser Kritik der SZ und was hält er vom Begriff des Kulturkämpfers Das alles hört ihr in der 60. Folge based. Unsere Kanäle: ⁠⁠⁠⁠⁠⁠Linktree based.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Paypal-Spende: ⁠⁠⁠⁠⁠⁠⁠⁠Monatlich oder einmalig⁠⁠⁠⁠.⁠ Patreon werden: ⁠⁠⁠⁠⁠Und bau unsere Community mit auf.

Stephen Grootes speaks to Telkom Group CEO Serame Taukobong about the company's half-year results, which showed a 1.8% decline in profit, but a notable 57.5% jump in adjusted headline earnings per share, driven by strong mobile data demand that boosted group revenue to R21.4 billion.See omnystudio.com/listener for privacy information.

In this podcast episode, Dr. Robert Whitfield, a board-certified plastic surgeon specializing in breast implant illness (BII), and Dr. Mithun Sinha, a PhD scientist, discuss the complexities of Breast Implant Illness. Dr. Whitfield shares his clinical experiences and emphasizes the importance of understanding the symptoms and experiences of women affected by Breast Implant Illness and Dr. Sinha provides scientific insights into the role of fatty acids, bacteria, and biofilm formation concerning breast implants, explaining how these factors contribute to symptoms like fatigue and brain fog. Be sure to tune in to hear more! Show Highlights: Role of Fatty Acids in Cell Structure (00:01:51) The importance of fatty acids in cellular stability and protection Interaction of Fatty Acids and Implants (00:03:20) Discussion on how fatty acids interact with breast implants and surrounding tissue Formation of 10 Home and Biofilms (00:05:20) Dr. Sinha describes how oleic acid transforms into 10 Home, linked to bacterial biofilms. Scar Capsule and Bacterial Colonization (00:06:40) Exploration of how the scar capsule provides a habitat for bacteria to form biofilms Historical Perspective on Surgical Techniques (00:12:40) Dr. Whitfield shares his experience with surgical techniques for patients with breast implant illness. Importance of Research on BII (00:13:41) Lack of attention to women suffering from BII and the need for better care Introduction to Oxaliplatin Home Research (00:14:54) Dr. Sinha introduces his new paper on oxaliplatin home and its link to inflammation Oxidation and Its Effects on the Body (00:16:04) Dr. Sinha explains how oxidation increases during stress and exercise, affecting health Potential Biomarkers for BII Symptoms (00:17:38) Discussion on identifying biomarkers to predict and assess symptoms in BII patients Characterizing Bacterial Contamination (00:19:54) Dr. Whitfield discusses the need to characterize bacterial contamination in patients with implants. Read Dr. Mithun Sinha's paper in The Aesthetic Surgery Journal. Oxylipins in Breast Implant–Associated Systemic Symptoms (https://academic.oup.com/asj/article/44/10/NP695/7690705) Bio. Mithun Sinha, PhD Dr. Sinha is an Assistant Professor in the Division of Plastic Surgery, Department of Surgery at the Indiana University School of Medicine. His laboratory specializes in the field of bacterial biofilm research. The investigations are focused on implant-associated complications due to biofilms and wound healing complications. These include breast implant-associated systemic immunological manifestations, dental implant-associated peri-implantitis, and orthopedic implant-associated osteomalacia. Studies also include wound healing studies exploring host-biofilm-mediated metabolites. His laboratory explores the development of implant-based biomaterials for their anti-biofilm properties. Over the years, he has actively collaborated with surgeons and chemical and material science engineers. He has been continually funded by NIH and currently have two active grants from NIH as PI (R01 and R21). He has also served/serving on 4 NIH grants as Co-Investigator. He has published 45 articles in peer-reviewed journals, with a Google Scholar citation of 2600+ and an h-index of 20. Seven of his publications have been cited 100+ times. A recent study from his lab on breast implant-associated immunological complications published in the Journal of Clinical Investigation (PMID: 38032740) has received editorial-type commentary from the peer community (PMID: 38299590). In addition to being a researcher, he has served as a reviewer for 15+ peer-reviewed journals. He also serves as Associate Editor for the journal RNA Biology and as an ad-hoc member of the NIH study section and Plastic Surgery Foundation (PSF) study panels. Connect with Dr. Whitfield: Podcast (https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554) Spotify (https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667) TikTok (https://www.tiktok.com/@drrobertwhitfield?_t=8oQyjO25X5i&_r=1) IG (https://www.instagram.com/breastimplantillnessexpert/) FB (https://www.facebook.com/DrRobertWhitfield) Linkedin (https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/) X.com (https://x.com/rjwhitfield?lang=en) Read this article (https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness) Shop Dr. Whitfield's Solutions (https://drrobssolutions.com) SHARP (https://www.harp.health) NVISN Labs (https://nvisnlabs.com/) Get access to Dr. Rob's Favorite Products below: Danger Coffee (https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg) - Use our link for mold-free coffee. JASPR Air Purifier (https://jaspr.co/)- Use code DRROB for the Jaspr Air Purifier. Echo Water (https://echowater.com/)- Get high-quality water with our code DRROB10. BallancerPro (https://ballancerpro.com) - Use code DRROBVIP for the world's leader in lymphatic drainage technology. Ultrahuman (https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield)- Use code WHITFIELD10 for the most accurate wearable.

In this podcast episode, Dr. Robert Whitfield, a board-certified plastic surgeon specializing in breast implant illness (BII), and Dr. Mithun Sinha, a PhD scientist, discuss the complexities of Breast Implant Illness. Dr. Whitfield shares his clinical experiences and emphasizes the importance of understanding the symptoms and experiences of women affected by Breast Implant Illness and Dr. Sinha provides scientific insights into the role of fatty acids, bacteria, and biofilm formation concerning breast implants, explaining how these factors contribute to symptoms like fatigue and brain fog. Be sure to tune in to hear more! Show Highlights: Role of Fatty Acids in Cell Structure (00:01:51) The importance of fatty acids in cellular stability and protection Interaction of Fatty Acids and Implants (00:03:20) Discussion on how fatty acids interact with breast implants and surrounding tissue Formation of 10 Home and Biofilms (00:05:20) Dr. Sinha describes how oleic acid transforms into 10 Home, linked to bacterial biofilms. Scar Capsule and Bacterial Colonization (00:06:40) Exploration of how the scar capsule provides a habitat for bacteria to form biofilms Historical Perspective on Surgical Techniques (00:12:40) Dr. Whitfield shares his experience with surgical techniques for patients with breast implant illness. Importance of Research on BII (00:13:41) Lack of attention to women suffering from BII and the need for better care Introduction to Oxaliplatin Home Research (00:14:54) Dr. Sinha introduces his new paper on oxaliplatin home and its link to inflammation Oxidation and Its Effects on the Body (00:16:04) Dr. Sinha explains how oxidation increases during stress and exercise, affecting health Potential Biomarkers for BII Symptoms (00:17:38) Discussion on identifying biomarkers to predict and assess symptoms in BII patients Characterizing Bacterial Contamination (00:19:54) Dr. Whitfield discusses the need to characterize bacterial contamination in patients with implants. Read Dr. Mithun Sinha's paper in The Aesthetic Surgery Journal. Oxylipins in Breast Implant–Associated Systemic Symptoms (https://academic.oup.com/asj/article/44/10/NP695/7690705) Bio. Mithun Sinha, PhD Dr. Sinha is an Assistant Professor in the Division of Plastic Surgery, Department of Surgery at the Indiana University School of Medicine. His laboratory specializes in the field of bacterial biofilm research. The investigations are focused on implant-associated complications due to biofilms and wound healing complications. These include breast implant-associated systemic immunological manifestations, dental implant-associated peri-implantitis, and orthopedic implant-associated osteomalacia. Studies also include wound healing studies exploring host-biofilm-mediated metabolites. His laboratory explores the development of implant-based biomaterials for their anti-biofilm properties. Over the years, he has actively collaborated with surgeons and chemical and material science engineers. He has been continually funded by NIH and currently have two active grants from NIH as PI (R01 and R21). He has also served/serving on 4 NIH grants as Co-Investigator. He has published 45 articles in peer-reviewed journals, with a Google Scholar citation of 2600+ and an h-index of 20. Seven of his publications have been cited 100+ times. A recent study from his lab on breast implant-associated immunological complications published in the Journal of Clinical Investigation (PMID: 38032740) has received editorial-type commentary from the peer community (PMID: 38299590). In addition to being a researcher, he has served as a reviewer for 15+ peer-reviewed journals. He also serves as Associate Editor for the journal RNA Biology and as an ad-hoc member of the NIH study section and Plastic Surgery Foundation (PSF) study panels. Connect with Dr. Whitfield: Podcast (https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554) Spotify (https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667) TikTok (https://www.tiktok.com/@drrobertwhitfield?_t=8oQyjO25X5i&_r=1) IG (https://www.instagram.com/breastimplantillnessexpert/) FB (https://www.facebook.com/DrRobertWhitfield) Linkedin (https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/) X.com (https://x.com/rjwhitfield?lang=en) Read this article (https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness) Shop Dr. Whitfield's Solutions (https://drrobssolutions.com) SHARP (https://www.harp.health) NVISN Labs (https://nvisnlabs.com/) Get access to Dr. Rob's Favorite Products below: Danger Coffee (https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg) - Use our link for mold-free coffee. JASPR Air Purifier (https://jaspr.co/)- Use code DRROB for the Jaspr Air Purifier. Echo Water (https://echowater.com/)- Get high-quality water with our code DRROB10. BallancerPro (https://ballancerpro.com) - Use code DRROBVIP for the world's leader in lymphatic drainage technology. Ultrahuman (https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield)- Use code WHITFIELD10 for the most accurate wearable.

Nuestros amigos de Planeta De Agostini que nos apoyan en este vídeo, hacen colecciones que me “flipan”, han lanzado una nueva que, personalmente, no me la voy a perder: Una maqueta espectacular del R8 Gordini, con licencia oficial de la propia Renault y a escala 1/6… o sea, ¡enorme! Tiene detalles únicos, como el motor reproducido fielmente, que parece que va a echar a andar, una reproducción perfecta del habitáculo y una decoración y neumáticos fieles, muy fieles al original. Y como colofón… ¡luces con mando a distancia! Muchos detalles, piezas de alta calidad en metal y plástico ABS, luces… seguro que estás pensado: “Esto sería complicado de montar”. Ya soy un experto en estas colecciones y te digo algo: Montarlo no solo es muy divertido, sino que es realmente fácil. Solo tienes que seguir las instrucciones y no tendrás el menos problema. Y lo de la escala 1/6 algo inédito… quieres toda la info, en el texto descriptivo tiene el link: https://bit.ly/GordiniGarajeHermetico A ver cuanto sabéis de coches: ¿Qué tienen en común el Ferrari Mondial y el Renault 21? Aparte, ¡claro! de tener 4 ruedas, un volante y un motor… pensad un poco… (ruido de tic, tac) …pensad… pues que son probablemente los únicos coches de la producción mundial que montaron motores transversales y longitudinales… Por motivos distintos, eso sí. Os lo vamos a contar en detalle, es una historia que vale la pena. Os doy un aviso: Este es un podcast técnico, pero “apto para todos los públicos”. Si sabes mucho de coches, esta historia te va a gustar, aunque la conozcas… y si sabes poco, también te va a interesar, porque es muy curiosa. Aunque todos lo sabéis, para los “nuevos” diré que el motor transversal es aquel cuyo cigüeñal es trasversal a la marcha, es decir, forma un ángulo de 90 grados con el eje longitudinal… algo que popularizo el ingenioso Mini de Alec Issigonis. Lo pintamos en la pizarra… el motor delantero con tracción delantera. Si es longitudinal, hay varias opciones, pero si el coche es tracción delantera, suele estará “colgado” por delante del eje delantero. Pero es que un motor puede ser transversal y central a la vez, como era el caso del Lamborghini Miura, lo que permite hacer el coche más corto… o puede ser central longitudinal, como el caso de otro “mito”, el Ferrari F40. También puede ser longitudinal y colgado por detrás, como el caso de los Porsche 911 o los Renault 8… Nacido para ser un superventas -superventas a lo “Ferrari”- el Mondial fue un fracaso. Ferrari decidió intentar que este modelo ganase el favor del público y de la prensa y para eso hacían falta, al menos 300 CV. Ferrari tenía motores de esa potencia… pero no para montar de forma transversal. Así que en 1989 presenta el Ferrari Mondial “T”, una T que hacía referencia a “Trasversale” o sea, “Transversal” y cuyo motor iba longitudinal…pero la caja de cambios que iba montada de forma transversal, un sistema curioso que le dió bueno frutos a la saga de Ferrari T de F1, que se llamaban así por el mismo motivo. Este modelo montaba un motor V8, como hemos dicho longitudinal, de 3,4 litros y 300 CV que, entre otras cosas, permitía bajar el centro de gravedad del coche en 12 cm, gracias a que el motor, con cárter seco, podía ir más bajo… En el caso del R21 su mayor curiosidad es que se presentaron a la vez modelos con el motor transversal y longitudinal… ¡del mismo coche! ¿El motivo? Pues que el R21 era el heredero del R18, y se situaba a medio camino entre el R19 por abajo y el R25 por arriba. El R19 con motores de hasta 1,7 litros diseñados para ser montados transversalmente. Los motores más “gordos”, de dos litros, incluso siendo de 4 cilindros no cabían trasversalmente en la carrocería diseñada, por cierto, por Giorgetto Giugiaro, tenían que ir de forma longitudinal… Así que diseñaron dos subchasis distintos para poder montar unos motores, los “pequeños”, transversales y los otros, los “grandes” longitudinales. ¿Mejor transversal o longitudinal? Pues según. En el caso del Ferrari el Mondial “T” con motor longitudinal no solo era más potente, sino que a nivel de comportamiento ganaba mucho, gracias a un centro de gravedad más bajo. No era así en el caso del R21, porque el motor transversal mejoraba el reparto de pesos y además era más ligero. Los modelos más potentes, con un motor más pesado y “colgado” por delante del eje delantero eran más torpes. El “Quadra” era y es una excepción pues al contar propulsión posterior adicional, con unos reglajes de suspensión claramente más firmes y un más generoso calzado, era sencillamente, “otro coche”.

¡Me encantan las comparativas de coches clásicos! No, no es cuestión de nostalgia… o no solo. Es que me encanta ver como coches que rivalizaban por los mismos compradores eran tan distintos entre sí. Estos grandes rivales de la España de los 70 y 80 eran muy diferentes… y los más vendidos, con diferencia, de su categoría. Tenían una cosa en común: Una gama muy amplia. Además de su amplia gama, tenían más cosas en común, como ser la evolución mejorada de los coches que les precedieron. Porque el R18 no era más que un R12 mejorado y más grande mientras que en el caso del Seat 131 no era más que un 124 más grande y puesto al día… pero manteniendo la tracción posterior y eje trasero rígido que ya, en esas fechas, eran una solución algo obsoleta. Primero veamos el “hilo” temporal. El Seat se comienza a vender en España en 1975, solo un año después de comenzar su venta en Italia el Fiat 131. La vida del Seat 131 seria larga, de nueve años, hasta 1984 cuando es sustituido por el Seat Málaga o, como leí en algún diario, el Seat Ronda “con culo”. El R18 apareció en España en 1978, solo meses después que en Francia. Su vida también fue de 9 años… en Europa. Porque en Argentina este modelo se mantuvo en producción y con notable éxito hasta 1993. Su sucesor, el R21 al contrario que lo sucedido con el Seat, se situaba incluso más por arriba del propio R18 y tuvo en enorme y merecido éxito… El Seat 131 fue la culminación de Fiat en cuanto a modelos con propulsión posterior. El 131 estaba más lejos del 124 que el R18 del R12. Porque sí, era una mejora del Seat 124, con una carrocería más grande, moderna, bonita, espaciosa y aerodinámica. Los R18 españoles y franceses eran los mismos. No exactamente porque con muy buen criterio no solo la definición de equipamiento, sino los reglajes de suspensión e incluso los desarrollos de los Renault fabricados es España se adaptaban a las peculiaridades de nuestras vías, con muchos menos kilómetros de autopistas y mayores pendientes. Pero en el caso de Seat la diferencia de los coches italianos y españoles era mayor y os explico los motivos, que son muy interesantes. Primero, porque se puede decir que en Italia el 131 rápidamente sustituye al 124, mientras que en España el éxito del modelo hace que convivan más años. En España no llegó nunca al Fiat 128, este sí de tracción delantera y que por tamaño, precio y segmento de mercado estaba más próximo al 1245 que el propio 131. El 131 fue diseñado en plena crisis del petróleo y se aprovechó para montar motores más modernos y económicos de consumo en cilindradas desde los 1,3 litros a los 1,6 que no llegaron a España, pues el 131 español utilizó los mismos motores que venía utilizando en sus Seat 124 y 1430 normales y especiales. El R18 nace en España con la versión GTS con un equipamiento tirando a generoso para le época y con motor de 1.647 cm3 y 79 CV, que luego fueron algunos más. En Francia había versiones más modestas, que como en el caso de Seat, se fabricaron en Valladolid, pero con la idea de ser destinadas a la exportación. En 1980 nacen las versiones Diesel con motor de 2.068 cm3 y 65 CV, que cuando llego el turbo un año después pasó a contar con 85 CV… un coche muy apreciado, pues disponía de las mismas o mejores prestaciones del original GTS de gasolina, pero con consumos mucho más ajustados. Y no me voy a olvidar del turbo, marca de la casa en esas fechas, con motor de 1.565 cm3 y 110 CV que, a partir de 1984, llegaron a los 125 CV. Los 131 españoles, como hemos dicho usaban motores propios. Con buen criterio el 1.124 cm3 de 65 CV se juzgó escaso para este coche cuya gama comenzaba con el 1.438 cm3 de 75 CV del Seat “catorce-treinta”. El siguiente motor era el 1.592 cm3 utilizado en los 124 más deportivos y en el Seat 132, con 95 CV. Y el motor estrella de los 131 más potentes, como el “Diplomatic” o el deportivo y precioso “CLX” era otro motor español, el de 1.919 cm3 y aa4 CV, una derivación del 1.995 cm3 de Fiat, pero reducido de cilindrada para acogerse a beneficios fiscales, por la fiscalidad en esos momentos “penalizaba la cilindrada”. Me gusta el Seat 131 pero si debo ser justo creo que el R18 fue mejor coche, al menos en España. ¿El motivo? Era un coche mucho más adaptado a la particulares condiciones del mercado español. Era muy cómodo en todo tipo de firmes, fácil de conducir y muy fiable. Si hablamos de versiones deportivas, ahí sí, creo que el 131 2.000 CLX era superior al R18 Turbo. Justo es reconocer que con la nueva suspensión de 1982 este modelo ganó en agilidad en curva, pero estaba lejos de eficacia deportiva del 131. Coche del día. Voy a elegir un Fiat 131… ¡pero el Abarth! ¡Que preciosidad! Un coche nacido, nada más y nada menos, que para sustituir al Lancia Stratos en los Rallyes… y que lo hizo con honor.

Oorstromings in Malmesbury en Chatsworth aangemeld nadat twee damwalle meegee. Twee mense word vermis weens die oorstromings. Die regering se voorwaardelike aanspreeklikhede vir openbare maatskappye, wat uit hofsake spruit, het teen einde Maart sowat R21 miljard beloop. Op die vooraand van Vrouedag kyk ons hoe verteenwoordigend vroue in die howe is.

FULL SHOW | Melbourne Captain, Max Gawn, hits the studio with big calls on R21. Bernard Fanning and Paul Dempsey discuss their NEW album, The Deluge. Parcel Parcel gets even better, and Rosie's Gig Guide is back!   Tune into Triple M weekdays LIVE from 6-9am for more Rosie, Wil and Daisy.   To watch your new breakfast crew in action, head to Youtube.  And for a laugh-fuelled feed, follow @triplemmelb on Instagram.   Remember to like and share!See omnystudio.com/listener for privacy information.

AJ and Rhys are back together as they recap Round 21 in a way that they know how. The boys review a sketchy win for the Wahs over the Tigers as they again rip on Andrew Webster;s bench rotation (he's not the only one we go after) as well as Stefano Utoikamanu's decision to leave. We review the Storm's win over Parra and the return of one C. Munster. Super Saturday saw wins to the Bulldogs as Rhys is raging over Brisbane's performance, the Cowboys as the Sharks middles earn criticism as well as Craig Fitzgibbon's bench. AJ's heart-rate rose signficiantly with the Roosters struggling to put away Manly. Sunday saw a ruthless win to Penrith, the Dolphins continuing second half fadeouts and the end of South Sydney's unlikely finals charge. We review R1 of the NRLW, R21 of the KOE NSW Cup and R20 (Country Week) in HostPlus Cup. We also keep tabs on our Olympic heroes during the program.

Paul Kagame is expected to record another enormous triumph in Monday's election. His 4000 troops supporting rebels in neighbouring Democratic Republic of Congo has slowed down the withdrawal of U.N. peacekeepers who have been there since 1999.  Another WHO-endorsed malaria  vaccine, R21 has been rolled out in Cote d'Ivoire. This is is half the price of the existing vaccine  RTS.S being introduced into  regular childhood immunisation schedules in Ghana, Kenya and Malawi.See omnystudio.com/listener for privacy information.

Os lo aviso… ¡este es un podcast raro! ¿Qué tienen en común un Audi Quattro, un Renault 12 y un Porsche 911?… ¡Que llevan el motor en el peor sitio posible! Colgando. Y no, no me refiero con el motor en el suelo, sino con el motor por delante del eje delantero o por detrás del eje trasero… donde en teoría no debería ir. Cuando era casi más un niño que un adolescente tenía dos iconos que me quitaban el sueño. Uno, que veía casi a diario, el R12. Mi otro icono era el Porsche 911, un coche del que estaba enamorado en ese momento… para mí era una estrella inalcanzable. Luego me hice mayor y otro coche me volvió a enamorar: El Audi Quattro, sobre todo las versiones de competición de Grupo B y sobre todo “La Bestia”, el Audi Quattro S1, acortado y con motores que llegaron según se dice a los 600 CV… La conclusión podría ser: Que tontos son los ingenieros que diseñaron estos coches y pudieron en motor ahí, donde destrozan el reparto de pesos y ofrecen un momento polar de inercia, para entendernos, una resistencia al girar, tremenda. Pues tiene su explicación. Pero para entenderla lo primero que hay que tener en cuenta es que un ingeniero no diseña según el humor, la idea o el pie con que se haya levantado esa mañana, sino que tiene un pliego de condiciones que tiene que cumplir. Y ese pliego de condiciones desde luego no lo prepara un ingeniero, sino un responsable de ventas, fabricación y marketing, que piden una cosa y la contraria y es el ingeniero el que tiene que intentar que todo lo que le piden sea posible… A la pregunta de ¿dónde debe ir el motor? La respuesta es, “según lo que quieras conseguir”. Es el momento de irnos a nuestra… “Pizarra Hermética”. Supongamos que queremos conseguir la máxima eficacia como coche deportivo. Obviamos, de momento, a los coches eléctricos. En un coche térmico las dos cosas que más pesan son el motor y los ocupantes, aunque sean solo dos. Lo ideal es que el peso vaya centrado, ligeramente cargando el tren posterior, y lo más bajo posible. Pero si lo que buscas no es estabilidad, sino espacio, lo mejor es poner el motor donde menos estorbe. Hasta que Alec Issigonis revoluciono todo con el Mini y su motor delantero transversal, cuando un ingeniero quería espacio interno para los pasajeros mandaba el motor lo más lejos posible. Eso significaba poner colgando por detrás, como hizo Dante Giacosa en 1957 en los Fiat 500 y después en los 600 y 850 o mandarlo al otro extremo, como hizo Audi en su primer Audi 100 de 1968 o Renault para su R12 en 1969. Comenzamos con los coches con el motor colgando por detrás del eje trasero y os recuerdo que ya hicimos un vídeo titulado “Coches todo atrás, porque son un peligro”. Pero vamos a recordar lo más interesante. El motor trasero hace que el comportamiento del coche sea delicado, en un primer momento le cuesta girar porque no tiene peso delante, pero luego una vez que gira como el motor trasero “tiende a seguir recto” hace que la trasera del coche se nos desmanda. La pregunta entonces es, ¿Por qué lo pusieron ahí? Es sencillo de entender, pero tienes que partir de una idea: Los neumáticos hasta digamos los años 80 y 90 no eran lo que son y la electrónica para ayudarnos en la conducción ni se la conocía si se la esperaba. Los coches eran mayoritariamente con el motor delantero y la propulsión posterior, con lo cual, a medida que aumentaba la potencia, la motricidad, la capacidad de pasar potencia al suelo, disminuía. Así que lo mejor era poner el motor encima del eje trasero. Esto no lo hizo solo Porsche ni fue la primera en hacerlo. Ya Tatra en 1934 lanzó en gran Tatra T77 con motor posterior, nada menos que un V8. Sus diseñadores fueron Hans Ledwinka y su hijo Erich… como curiosidad, te diré que ese coche tenía un CX de 0,212, que no superan ni de lejos los coches actuales. No me olvido del Audi Quattro. Pero es que el Quattro es un derivado del primitivo 100, del que se hicieron versiones más pequeñas y versiones Coupé y sobre un Audi Coupé, con motor turbo y tracción total, nace el Quattro. Y, por cierto, tampoco me olvido del Renault Fuego, un derivado del R18, por tanto, del R12 y con el motor “colgandero” ni de los Alfa Romeo Alfasud Sprint, entre otros. Renault usó está técnica en el R18 y luego, parcialmente, en el R21, que según el motor que llevase iba transversal o longitudinal por delante del eje trasero… que yo sepa en único coche que ofrecía ambas opciones. También en el R25 y en el Safrane. Audi siguió utilizando esta disposición en los 100 los 200 y todos sus derivados, incluido los Coupé y los citados Quattro. La cosa cambia en 1996 cuando aparece el Audi A3, en realidad un Golf vestido de Audi, pero obviamente con motor transversal.

Unicef-OMS-GAVI. Envío de la última vacuna contra la malaria, la R21 a RCA, un hito para la supervivencia infantil. Hablamos con Rebecka Jonsson, experta en vacunas en Unicef.La campaña Desayunos y Meriendas con Corazón, recauda 222.639 euros para familias en situación de vulnerabilidad. Fernando Cuevas responsable de campañas del área de inclusión social de Cruz Roja.Colaboración humanitaria para hacer protagonistas de su progreso a los sanitarios de los países receptores. Entrevistamos a la Dra. Virginia Durán, cirujana, y patrona de la Fundación SEMG.Escuchar audio

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Today is World Malaria Day (April 25), published by tobytrem on April 25, 2024 on The Effective Altruism Forum. Malaria is massive. Our World in Data writes: "Over half a million people died from the disease each year in the 2010s. Most were children, and the disease is one of the leading causes of child mortality." Or, as Rob Mather, CEO of the Against Malaria Foundation (AMF) phrases it: the equivalent of seven jumbo jets full of children die of Malaria each day. But I don't see malaria in the news that much. This is partly because it was eradicated from Western countries over the course of the 20th century, both because of intentional interventions such as insecticide, and because of the draining of swamp lands and building of better housing. But it's also because malaria is a slow catastrophe, like poverty, and climate change. We've dealt with it to varying degrees throughout history, and though it is an emergency to anyone affected by it, to the rest of us, it's a tropical disease which has been around forever. It can be hard to generate urgency when a problem has existed for so long. But there is a lot that we can do. Highly effective charities work on malaria; the Against Malaria Foundation (AMF) distributes insecticide treated bed-nets, and a Malaria Consortium program offers seasonal malaria chemoprevention treatment- both are GiveWell Top Charities. Two malaria vaccines, RTS,S and the cheaper R21[1], have been developed in recent years[2]. Malaria is preventable. Though malaria control and eradication is funded by international bodies such as The Global Fund, there isn't nearly enough money being spent on it. AMF has an immediate funding gap of $185.78m. That's money for nets they know are needed. And though vaccines are being rolled out, progress has been slower than it could be, and the agencies distributing them have been criticised for lacking urgency. Malaria is important, malaria is neglected, malaria is tractable. If you want to do something about malaria today, consider donating to Givewell's recommendations: AMF, or the Malaria Consortium: Related links I recommend Why we didn't get a malaria vaccine sooner; an article in Works in Progress. WHO's World Malaria Day 2024 announcement. The Our World in Data page on malaria. Audio AMA, with Rob Mather, CEO of AMF (transcript). From SoGive, an EA Forum discussion of the cost-effectiveness of malaria vaccines, with cameos from 1DaySooner and GiveWell. For more info, see GiveWell's page on malaria vaccines. The story of Tu Youyou, a researcher who helped develop an anti-malarial drug in Mao's China. What is an Emergency? The Case for Rapid Malaria Vaccination, from Marginal Revolution. More content on the Forum's Malaria tag. ^ R21 offers up to 75% reduction of symptomatic malaria cases when delivered at the right schedule. ^ Supported by Open Philanthropy and GiveWell. Thanks for listening. To help us out with The Nonlinear Library or to learn more, please visit nonlinear.org

Ava's severe squint requires surgery to repair two eye muscles. Her family lacks the finances for the procedure, but they've found a generous ophthalmologist who will perform it for free, covering aftercare. They need R21,000 for the anaesthetist and theatre costs. This surgery is vital for Ava to achieve single, binocular vision, improving her ability to read, perceive depth, and function visually. Hot Cares

Like many organizations, Open Philanthropy has had multiple founding moments. Depending on how you count, we will be either seven, ten, or thirteen years old this year. Regardless of when you start the clock, it's possible that we've changed more in the last two years than over our full prior history. We've more than doubled the size of our team (to ~110), nearly doubled our annual giving (to >$750M), and added five new program areas. As our track record and volume of giving have grown, we are seeing more of our impact in the world. Across our focus areas, our funding played a (sometimes modest) role in some of 2023's most important developments: We were among the supporters of the clinical trials that led to the World Health Organization (WHO) officially recommending the R21 malaria vaccine. This is the second malaria vaccine recommended by WHO, which expects it [...] --- First published: March 27th, 2024 Source: https://forum.effectivealtruism.org/posts/couP8n3BTrpFA5YDJ/open-philanthropy-our-progress-in-2023-and-plans-for-2024-1 Linkpost URL:https://www.openphilanthropy.org/research/our-progress-in-2023-and-plans-for-2024/ --- Narrated by TYPE III AUDIO.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Open Philanthropy: Our Progress in 2023 and Plans for 2024, published by Alexander Berger on March 27, 2024 on The Effective Altruism Forum. Like many organizations, Open Philanthropy has had multiple founding moments. Depending on how you count, we will be either seven, ten, or thirteen years old this year. Regardless of when you start the clock, it's possible that we've changed more in the last two years than over our full prior history. We've more than doubled the size of our team (to ~110), nearly doubled our annual giving (to >$750M), and added five new program areas. As our track record and volume of giving have grown, we are seeing more of our impact in the world. Across our focus areas, our funding played a (sometimes modest) role in some of 2023's most important developments: We were among the supporters of the clinical trials that led to the World Health Organization (WHO) officially recommending the R21 malaria vaccine. This is the second malaria vaccine recommended by WHO, which expects it to enable "sufficient vaccine supply to benefit all children living in areas where malaria is a public health risk." Although the late-stage clinical trial funding was Open Philanthropy's first involvement with R21 research, that isn't the case for our new global health R&D program officer, Katharine Collins, who invented R21 as a grad student. Our early commitment to AI safety has contributed to increased awareness of the associated risks and to early steps to reduce them. The Center for AI Safety, one of our AI grantees, made headlines across the globe with its statement calling for AI extinction risk to be a "global priority alongside other societal-scale risks," signed by many of the world's leading AI researchers and experts. Other grantees contributed to many of the year's other big AI policy events, including the UK's AI Safety Summit, the US executive order on AI, and the first International Dialogue on AI Safety, which brought together scientists from the US and China to lay the foundations for future cooperation on AI risk (à la the Pugwash Conferences in support of nuclear disarmament). The US Supreme Court upheld California's Proposition 12, the nation's strongest farm animal welfare law. We were major supporters of the original initiative and helped fund its successful legal defense. Our grantees in the YIMBY ("yes in my backyard") movement - which works to increase the supply of housing in order to lower prices and rents - helped drive major middle housing reforms in Washington state and California's legislation streamlining the production of affordable and mixed-income housing. We've been the largest national funder of the YIMBY movement since 2015. We've also encountered some notable challenges over the last couple of years. Our available assets fell by half and then recovered half their losses. The FTX Future Fund, a large funder in several of our focus areas, including pandemic prevention and AI risks, collapsed suddenly and left a sizable funding gap in those areas. And Holden Karnofsky - my friend, co-founder, and our former CEO stepped down to work full-time on AI safety. Throughout these changes, we've remained devoted to our mission of helping others as much as we can with the resources available to us. But it's a good time to step back and reflect. The rest of this post covers: Brief updates on grantmaking from each of our 12 programs. Our leadership changes over the past year. Our chaotic macro environment over the last couple of years. How that led us to revise our priorities, and specifically to expand our work to reduce global catastrophic risks. Other lessons we learned over the past year. Our plans for the rest of 2024. Because it feels like we have more to share this year, this post is longer and aims to share more than I have the last two...

Cameroon has begun the world's first major malaria vaccine program for children.喀麦隆已启动世界上第一个针对儿童的大型疟疾疫苗计划。The campaign launched Monday in the Central African nation. Health officials called the effort a major step in the fight against the disease across Africa. The continent accounts for about 95 percent of the world's malaria deaths.该活动周一在这个中非国家发起。 卫生官员称这一努力是整个非洲抗击这种疾病的重要一步。 非洲大陆约占世界疟疾死亡人数的 95%。The World Health Organization (WHO) estimates the disease, which is spread through mosquitos, kills more than 600,000 people a year. Most of the deaths involve young children.世界卫生组织 (WHO) 估计，这种通过蚊子传播的疾病每年导致超过 60 万人死亡。 大多数死亡涉及幼儿。The vaccine, called RTS.S, was developed by British drug company GlaxoSmithKline (GSK). It is meant to work with other preventive measures, such as the use of bed nets, to fight the disease.该疫苗名为RTS.S，由英国制药公司葛兰素史克（GSK）开发。 它旨在与其他预防措施（例如使用蚊帐）一起对抗这种疾病。Cameroon is the first country to offer vaccine injections through a routine program after successful tests, or trials, were carried out in Ghana and Kenya. Cameroon hopes to vaccinate about 250,000 children this year and next.在加纳和肯尼亚进行成功的测试或试验后，喀麦隆成为第一个通过常规计划提供疫苗注射的国家。 喀麦隆希望今明两年为约25万名儿童接种疫苗。The international vaccine alliance called Gavi has said 19 other countries aim to launch their own campaigns this year. About 6.6 million children in those countries are to receive malaria vaccinations in 2024 and 2025.名为 Gavi 的国际疫苗联盟表示，其他 19 个国家计划在今年发起自己的疫苗接种运动。 2024 年和 2025 年，这些国家约有 660 万儿童将接受疟疾疫苗接种。"For a long time, we have been waiting for a day like this," said Mohammed Abdulaziz. He is with the African Centers for Disease Control and Prevention. Abdulaziz spoke during a joint news briefing with the WHO, Gavi and other organizations.穆罕默德·阿卜杜勒阿齐兹说：“很长一段时间以来，我们一直在等待这样的一天。” 他在非洲疾病控制和预防中心工作。 阿卜杜勒阿齐兹在与世界卫生组织、全球免疫联盟和其他组织举行的联合新闻发布会上发表了讲话。Cameroon is using one of two recently approved malaria vaccines, called Mosquirix. When the WHO approved the vaccine two years ago, officials admitted it was not perfect. But they noted its use could sharply reduce severe infections and hospitalizations.喀麦隆正在使用最近批准的两种疟疾疫苗之一，称为 Mosquirix。 当世界卫生组织两年前批准该疫苗时，官员们承认它并不完美。 但他们指出，它的使用可以大幅减少严重感染和住院治疗。The GSK-produced shot is only about 30 percent effective. It requires four shots, or doses. Tests have shown the vaccine's protection begins to weaken after several months. GSK has said it can only produce about 15 million doses of Mosquirix a year.葛兰素史克生产的注射剂只有约 30% 的效率。 它需要四次注射或剂量。 测试表明疫苗的保护作用在几个月后开始减弱。 GSK 表示，每年只能生产约 1500 万剂 Mosquirix。Some experts believe a second malaria vaccine developed by Oxford University and approved by the WHO in October may be a better solution. That vaccine, called R21, is less costly and only requires three doses.一些专家认为，由牛津大学开发并于 10 月获得世界卫生组织批准的第二种疟疾疫苗可能是更好的解决方案。 这种疫苗称为 R21，成本较低，并且只需要三剂。

A new documentary tells a story of global scientific collaboration in the development of a new malaria vaccine, R21. Today, we take you behind the scenes with director and producer, Catherine Gale. In this podcast, we ask: Why are malaria vaccines gaining so much attention now? What was the serendipidous origin of the documentary? What are the key moments of the documentary? What is the role of collaboration in scientific discovery? With Catherine, Producer and Director at Wingspan Productions, and Bill Moss, a Deputy Director at the Johns Hopkins Malaria  About The Podcast The Johns Hopkins Malaria Minute is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.

A new documentary from NOVA shines a light on the creation of R21, a new malaria vaccine. Transcript This month, a new documentary from NOVA shines a light on the creation of a new malaria vaccine. ‘The Battle to Beat Malaria' tells the story of the development of R21 – from creation to WHO approval. Taking you behind the scenes in Oxford, UK, where the jab was developed as a PhD project, to the Serum Institute of India where millions of doses are prepared and stored. The documentary reveals the challenge of increasing the amount of protein that the vaccine creates, thereby the number of protective antibodies that the body creates. Of 142 vaccines developed, only a handful made it to clinical trials. And only two of those were approved for widespread use, R21 included. Through trial and error, the Oxford group eventually reached between 70 and 80% efficacy. Source The Batte to Beat Malaria (via PBS) About The Podcast The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Malaria vaccines: how confident are we?, published by Sanjay on January 5, 2024 on The Effective Altruism Forum. Alternative title: should SoGive red-team malaria vaccines? We've been seeing a lot of excitement about malaria vaccines - e.g. the first thing mentioned by the EA wins 2023 post was the R21 vaccine. We at SoGive looked into malaria vaccines about a year ago, and came away with a slightly more cautious impression. Bear in mind though, (a) we were trying to answer a different question[1]; (b) a lot has changed in a year. The purpose of this post is to outline these (currently tentative) doubts, and explore whether there's appetite for us to research this more carefully. The main things we're still unsure of At first glance, malaria vaccines appear less cost-effective than existing malaria interventions (nets/SMC[2]). Are they, in fact, less cost-effective? In light of this, does it make sense to advocate for their rollout? We thank 1Day Sooner for their helpful comments and constructive collaboration - we sent them a draft of this shortly before publishing. We also thank our contacts at Malaria Consortium and AMF; when we spoke to them in 2022 for our earlier review of malaria vaccines, their comments were very helpful. Some earlier work done by current/former members of the SoGive team has also provided useful groundwork for the thinking here, so thank you to Isobel Phillips, Ishaan Guptasarma, Scott Smith. Be aware that any indications of cost-effectiveness in this post are extremely rough, and may change materially if we were to conduct this research. Malaria vaccines may be materially (10x??) less effective than nets/SMC Based on the research we did a year ago, it seems that malaria vaccines significantly underperform bednets and SMC. Several items in this table are caveated; it's worth reviewing the version in the appendix which sets out the details. Several items in this table are caveated; it's worth reviewing the version in the appendix which sets out the details. RTS,S vaccine R21 vaccine Bednets* Cost-related considerations Cost per person treated $56.40 (estimated) >$8, based on WHO info; ~$25, based on info from 1Day Sooner $2.18 Number of doses needed per person 4 (i.e. 3 + a booster) 4 (i.e. 3 + a booster) 0.49 bednets per person protected Logistics: cold chain? Yes Yes, but less demanding than RTS,S No Efficacy-related considerations Reduction in clinical malaria** 55.8% 77% 45% Reduction in severe malaria** 32.2% Unknown, estimated at 44.4% 45% * SMC is only excluded from this table for brevity, not because of any preference for bednets over SMC. ** Malaria reduction figures are estimates under study conditions Vaccine costs look high… When we created this table c.1 year ago, the key message from this table is that costs for vaccines are materially higher than for bednets or SMC, which is significantly driven by logistical difficulties, such as the need for multiple doses and a cold supply chain (i.e. the vaccines have to be kept at a low temperature while they are transported). At the time, we focused on RTS,S because there was more information available. At that stage, we guessed that R21 would likely have similar costs to RTS,S. Somewhat to our surprise, it does seem that R21 costs may be lower than RTS,S costs. We weren't clear on the costs of R21, however when we shared a draft of this with 1Day Sooner, they helpfully pointed us to their Dec 2023 Vaccination Status Report. It seems they believe that each dose costs $3.90 on its own, and the all-in cost of delivering the first dose to a person is $25 per full course. ... and there doesn't * seem * to be an offsetting efficacy benefit. Although the efficacy numbers look similar, there are several complicating factors not captured in this table. For example, a consideration about the ages ...

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Malaria vaccine R21 is pre-qualified, published by JoshuaBlake on December 22, 2023 on The Effective Altruism Forum. WHO announced yesterday (21st December) that they have added the malaria R21 vaccine to their pre-qualified list. This is the regulatory step required for Gavi to begin their programmes, as previously discussed on the forum. A good day! Thanks for listening. To help us out with The Nonlinear Library or to learn more, please visit nonlinear.org

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Suggestions for Individual Donors from Open Philanthropy Staff - 2023, published by Alexander Berger on December 20, 2023 on The Effective Altruism Forum. In past years, we sometimes published suggestions for individual donors looking for organizations to support. This post shares new suggestions from Open Philanthropy program staff who chose to provide them. Similar caveats to previous years apply: These are reasonably strong options in the relevant focus area, and shouldn't be taken as outright recommendations (i.e., it isn't necessarily the case that the person making a suggestion thinks that their suggestion is the best option available across all causes). The recommendations below fall within the cause areas Open Philanthropy has chosen to focus on. While this list does not expressly include GiveWell's top charities, we believe those organizations to be among the most cost-effective, evidence-backed giving opportunities available to donors today, and expect that some readers of this post might want to give to them. Many of these recommendations appear here because they are particularly good fits for individual donors. This shouldn't be seen as a list of our strongest grantees overall (although of course there may be overlap). Our explanations for why these are strong giving opportunities are very brief and informal, and we don't expect individuals to be persuaded by them unless they put a lot of weight on the judgment of the person making the suggestion. In addition, these recommendations are made by the individual program officers or teams cited, and do not necessarily represent my (Alexander's) personal or Open Philanthropy's institutional "all things considered" view. Global Health and Development 1Day Sooner Recommended by Chris Smith What is it? 1Day Sooner was originally created during 2020 to advocate for increased use of human challenge trials in Covid vaccines, and named on the basis that making vaccines available even one day sooner would be hugely beneficial. 1DS is now expanding its work to look at other diseases where challenge trials could be safe, such as hepatitis C, where Open Philanthropy separately has grants developing new vaccine candidates. Open Philanthropy has supported 1DS from both our GHW and GCR portfolios. Why I suggest it: Recently, 1DS have been working on accelerating the global rollout of vaccines beyond the increased use of challenge trials, such as their current campaign on R21. R21 is an effective malaria vaccine (developed in part by Open Philanthropy Program Officer Katharine Collins while she was at the Jenner Institute) recommended for use by WHO in October 2023 but with plans only to distribute fewer than 20 million doses in 2024, despite the manufacturer claiming the ability to make 100 million doses available. You can read an op-ed on this from Zacharia Kafuko, Africa Director of 1DS, in Foreign Policy. If 1DS can diversify its funding base and find more donors, they'd have the capacity to take on other projects that could accelerate vaccine development and distribution. I've been impressed with their work on both policy and advocacy, and I plan to support them myself this year. (Also, personally, I really enjoy supporting smaller organizations as a donor; I find that this helps me "feel" the difference more than if I'd donated to a large organization.) How to donate: You can donate here. Center for Global Development Recommended by Lauren Gilbert What is it? The Center for Global Development (CGD) is a Washington D.C.-based think tank. They conduct research on and promote evidence-based improvements to policies that affect the global poor. Why I suggest it: We've supported CGD for many years and have recommended it for individual donors in previous years. CGD has an impressive track record, and it continues to do impac...

Annoncées en octobre 2021 par l'Organisation mondiale de la santé (OMS), les premières livraisons du vaccin antipaludique (RTS, S) ont démarré le 21 novembre. Plus de 330.000 doses du vaccin ont ainsi été livrées au Cameroun après une phase pilote au Ghana, au Kenya et au Malawi. Une étape clé qui prépare le terrain pour une vaccination à grande échelle sur le continent. Pour le docteur Charles Shey Wiysonge, chargé de l'immunisation au bureau régional de l'OMS, cette tournée de vaccinations marque « une étape historique » dans la lutte contre le paludisme. Il est l'invité de Christina Okello. RFI : Quelle est la spécificité du vaccin RTS,S ?Charles Shey Wiysonge : Il s'agit du premier vaccin antipaludique recommandé par l'OMS pour prévenir le paludisme chez les enfants. Le vaccin agit contre le Plasmodium falciparum qui est le parasite du paludisme le plus meurtrier dans le monde et celui qui est le plus présent en Afrique. Les recommandations de l'OMS concernant ce vaccin antipaludique reposent sur les résultats du programme pilote de mise en œuvre du vaccin qui a été conduit dans trois pays, au Ghana, Kenya et Malawi.Le Cameroun n'avait pas participé au programme pilote de vaccination, pourquoi a-t-il été choisi pour recevoir les premières doses ?Le Cameroun, et d'autres pays, vont recevoir la livraison dans les prochaines semaines, ce sont les premiers pays qui ont soumis une demande de soutien à Gavi, l'Alliance du vaccin. Puisque la forte demande a dépassé l'offre disponible, on a limité l'allocation de stocks parce qu'on a environ 18 millions de doses, donc avec 28 pays, c'était difficile. Donc il y en a un quart qui a été développé avant que les pays ne fassent la demande.Quelle est la situation du paludisme au Cameroun, et ailleurs ?Dans les pays comme le Cameroun, le Nigeria, c'est vraiment un grand problème de santé publique. Il y a au moins 10% de la population qui est atteinte du paludisme.Quelle est l'importance de ce vaccin pour la lutte contre le paludisme ? C'est une étape très importante parce que le vaccin est très efficace pour réduire le nombre de cas de paludisme causé par le Plasmodium falciparum chez les jeunes enfants et il réduit les formes graves. Après l'introduction du vaccin dans le programme pilote, on a constaté une baisse très remarquable du nombre d'enfants hospitalisés et une diminution du nombre de décès chez les enfants d'environ 13%. Donc c'est vraiment important.Quelle est l'efficacité du vaccin RTS,S compte tenu de la résistance du paludisme aux médicaments ?Il y a une résistance seulement quand quelqu'un a déjà le paludisme. On a vu qu'après trois doses de ce vaccin, il y a une diminution de 75% des cas de paludisme pendant la première année. C'est vrai que l'efficacité diminue, c'est pour cela qu'on recommande qu'un an après la troisième dose, il faut en donner une quatrième, et aussi un an après ça, il en faut une cinquième. Qui peut prendre le vaccin RTS,S ?On recommande quatre doses aux enfants à partir de l'âge de cinq mois. Par exemple, au Cameroun, le calendrier vaccinal prévoit qu'il y ait quatre doses, à six mois, à sept mois, à neuf mois et à vingt-quatre mois d'âge. C'est seulement pour les enfants.Le mois dernier, l'OMS a donné son feu vert à l'utilisation pour les enfants d'un deuxième vaccin antipaludique, le R21, quelle est la différence avec le vaccin RTS,S ?Il n'y a pas de différence, les deux vaccins agissent de la même manière. Mais pour le premier vaccin, il y a seulement, environ, dix-huit millions de doses qui seront disponibles d'ici 2025. Ce n'est pas suffisant. Au moins vingt-huit pays d'Afrique envisagent d'introduire ces vaccins contre le paludisme dans leur programme de vaccination d'enfants. Mais ce qui est aussi important, c'est que l'autre vaccin, le fabriquant a dit qu'ils vont produire beaucoup plus de doses que dix-huit millions, donc d'ici la fin de l'année prochaine, on n'aura pas de problèmes de stocks limités.Après le Cameroun, quels sont les prochains pays destinataires du vaccin?Après le Cameroun, il y aura le Burkina Faso, le Liberia, il y aura le Niger et la Sierra Leone. D'après les nouvelles qu'on a, le gouvernement du Cameroun prévoit de commencer la campagne de vaccination le 12 décembre. Quand va démarrer la vaccination à grande échelle sur le continent ?Chaque pays a son calendrier. Par exemple, le Cameroun va commencer en décembre. Il y a d'autres pays, comme le Burkina Faso, il y a le Burundi, il y a la RDC, on prévoit qu'il y aura cinq pays entre janvier et juin, parce qu'on pense que l'autre vaccin R21 sera disponible à partir de juin. Donc on pense qu'il y aura un peu plus de pays après juin.Et que signifie pour l'Afrique cette vaccination à grande échelle ?Chaque année, il y a autour de 500 000 enfants qui meurent dans le monde et la plupart, 95%, sont en Afrique. Si on a un vaccin, il va diminuer ce taux de mortalité. On a vu la réduction du taux de mortalité au Ghana, au Kenya, au Malawi, autour de 13%. Vous imaginez, un taux de réduction de 13% de la mortalité ? Et il y a une diminution des cas de paludisme de 75%. Donc c'est un grand atout pour la lutte contre le paludisme, je pense que c'est un moment historique pour l'Afrique et pour la vaccination en général.

Noluthando Mthonti-Mlambo speaks Telkom Group CEO, Serame Taukabong about the company's results. The results show improved financial performance, with group revenue up 2.5% to R21.8 billion and earnings before interest, taxes, depreciation and amortisation up 1.7% to R5.025 billion. Headline earnings per share improved 46.7% to 195c and basic earnings per share were up 52.1% to 200.2c.See omnystudio.com/listener for privacy information.

Tổ chức Y tế Thế giới WHO đã cấp phép cho một loại vắc-xin sốt rét mới có tên là R21, do các nhà khoa học thuộc Đại học Oxford phát triển, là loại thuốc chủng thứ hai được tạo ra. WHO cho biết mặc dù vắc xin trước đây cũng có hiệu quả, nhưng loại mới có thể được sản xuất ở quy mô lớn hơn và rẻ hơn nhiều.

Die Debatte über die Integration von Muslimen, sie gleicht oft einem Minenfeld. Die Fronten sind ideologisch verhärtet. Einen kritischen Blick auf die Debattenkultur rund um die Integration hat unser Gast von der Goethe-Universität Frankfurt, die deutsche Ethnologin, Islamforscherin und Direktorin des Frankfurter Forschungszentrums Globaler Islam (FFGI) und Gründungsmitglied des bürgerlichen Thinktank Republik 21 - R21, Professor Dr. Susanne Schröter. Scheitert der Westen angesichts der aktuellen Krisen an seiner eigenen Doppelmoral? Wie geeint ist die vermeintliche Geschlossenheit, wenn es um nationale Interessen geht? Als Antwort auf diese Fragen diagnostiziert Susanne Schröter, in ihrem jüngsten Buch „Global gescheitert? Der Westen zwischen Anmaßung und Selbsthass.” ein tiefgreifendes strukturelles Problem des Westens.Az MCC Podcast adásaiban érdekes emberekkel izgalmas témákról beszélgetünk. Feldolgozzuk a közélet, a gazdaság, a társadalom fontosabb aktuális történéseit, de olyan kérdéseket is napirendre veszünk, mint például a művészet, a család vagy a vallás. Vendégeink között oktatóink, kutatóink, vendégelőadóink kapnak helyet. Mindenkinek kellemes időtöltést és szellemi feltöltődést kívánunk.

On a YUGE episode, we go through it all:

Celebrated analyst, broadcaster, and author Eusebius McKaiser has passed away, unaudited results disclosed by the National Treasury shows a R21.2-billion loss for Eskom, and much more. Here is a recap on this morning's five things. #FiveThingsYouNeedToKnow: Disruptive rain expected in parts of KZN · Webpage

More than a quarter of the world's malaria cases happen in Nigeria according to the World Health Organisation. This week the country became the second, after Ghana to provisionally approve the use of malaria vaccine R21. Professor Matt Fox explains why scientists have called the vaccine a ‘world changer'. We hear from dementia nurse Kemi Reeves who supports people living with dementia in Los Angeles. Her project has recently been shown to reduce the cost of caring for people with Alzheimers. We also hear about a new piece of research from the UK showing that hearing aids may protect against a higher risk of dementia. As we learn more about ‘Long Covid', we explore evidence that links breathlessness with having had disrupted sleep. And have you ever been told you grind your teeth? Author Naomi Alderman was shocked recently when visiting the dentist to be told she had a condition called bruxism and hadn't even realised. We ask whether experiencing the Covid pandemic may have led to more of us griding and clenching our teeth. Image Credit: Halfpoint Images Presenter: Claudia Hammond Producer: Clare Salisbury

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: My experience getting funding for my biological research, published by Metacelsus on April 16, 2023 on LessWrong. Linked from my Substack Research is expensive, especially these days. Even though grad students and postdocs are underpaid, it still costs a lot to employ them. And every year, lab suppliers increase their prices. Overall, it continually gets more expensive to do the same amount of work: Therefore, in order to carry out my meiosis project, I needed a source of funding. I am just a grad student and usually it is a professor's job to get grants, but for various reasons I decided to take matters into my own hands. After my experience with the F31 fellowship and all its paperwork, I was rather turned off by the prospect of applying for an NIH grant (R01 or R21). In the best case, I would have to write a huge application, then wait for months before hearing if it was funded, then more months before actually being able to spend anything. And of course, funding chances are always low with the NIH. So, I decided to seek out private philanthropic funding. This, as it turned out, was not as simple as I had expected. Timeline of events September 2022 I develop my project idea and figure out roughly how much funding I need ($300,000 per year over two years, to cover salaries and lab supplies). I reach out to some potential funders. I quickly focus on the FTX Future Fund, since they are known to have a giant pile of cash they want to get rid of. October 2022 I write a formal research proposal and submit it to some FTX Future Fund regrantors. I also start meeting with some university admins who manage research finances. They agree that we can set the overhead rate at 15%. October 29: I meet with the regrantors who tell me they are excited about the project. November 2022 November 3: The FTX Future Fund regrantors announce that they've approved the grant, and can I please send them my bank account info for them to wire $300,000? But before we can accept the funds, my university needs to do due diligence to make sure they're not criminals. The Jeffrey Epstein scandal created some strong organizational scar tissue. Perhaps this is a good thing, because . . . November 8: November 14: It's confirmed that I won't be seeing a cent of the $300,000 from the FTX Future Fund. Well, at least I am not at risk of clawbacks. Late November: I meet with various other philanthropists, and receive multiple suggestions to apply for a Survival and Flourishing Fund (SFF) Speculation Grant. I start working on the application. November 17: The Repro Grants are announced. This seems like a perfect fit for my research. November 20: I submit my initial Repro Grant application. Overall I spent about 6 hours writing it (they claimed it would take 30 minutes, but it's certainly better than the 100 hours I spent on the F31). December 2022 December 7: I hear that my initial Repro Grant application was not funded. However, there is still time left in the application period, so I spend another ~6 hours writing a different proposal (focusing on ovarian organoids instead of meiosis). December 22: I submit my application for a SFF Speculation Grant. Around this time, I am also discussing the project with two private donors who may be interested in funding it. One of these backs out (due, I think, to losing money in the crypto downturn), but the other one is very excited about it. December 29: SFF agrees to provide $401,000 for the project, with the private donor also providing $300,000. This is at the high end of my requested budget, so I am especially happy about it. January 2023 January 3: The Repro Grant was funded! Although they only gave me $65,000 out of the $100,000 I requested, it's still excellent news. Early January: University admins agree to accept the money from SFF and the Repro Grant. Howev...

Durante muchos años la mayor parte de los modelos de Renault tenían como nombre un simple número. Pero, a diferencia de otras marcas, en las que el número era una pista, en Renault el número despista. Así que vamos a repasar todos… del R3 al R900, ¿o no sabías que hubo un R900, una especie de monovolumen con motor V8? ¡Hoy nos vamos a divertir! Porque es cierto que en otras marcas la numeración te da una pista. Pongamos por ejemplo BMW. Sabes que el primer número te da una referencia de la categoría del coche, un serie 3 es más que un serie 1 y menos que un serie 5. Además, los impares son 4 puertas laterales y los pares 2. Y las dos siguientes cifras te orientan sobre la cilindrada… todo muy organizadito y muy alemán… algo parecido hace, por ejemplo, Mercedes-Benz. Pues en Renault resulta que un R15 es un deportivo y que un R16 es una berlina media. Un R10 es un tres volúmenes, pero el R9 es también 3 volúmenes, como el R12… pero en cambio el R11 es dos volúmenes… ¡Vaya lio! ¿O no? Pues la verdad es que no. Cierto que no hay una lógica “global” pero por el conocimiento de la marca y de los modelos lo cierto es que la inmensa mayoría de los casos nadie tiene ningún problema para saber de qué coche hablamos. Hay excepciones, como el R3 que no todo el mundo conoce, o el R7 que no lo hubo en todos los países, o los R15, R15 y R17 no muy conocidos en España. Y la estrella del video de hoy, el R900. Y empezamos, por orden ascendente y con una advertencia: NO hemos tenido en cuenta los coches de competición sobre todo los F1. ¡Vamos allá! R3 (1961), R4 (1961), R5 (1972), R6 (1968), R7 (1974), R8 (1962), R9 (1981), R10 (1965), R11 (1981), R12 (1969), ¿R12+1?, R14 (1976), R15 (1971), R16 (1965), R17 (1971), R18 (1978), R19 (1988), R20 (1975), R21 (1986), R25 (1983), R30 (1975) y R900 (1959) Conclusión. ¿Me he olvidado de alguno? Espero vuestros comentarios . Y en un próximo vídeo, los F1. Coche del día. Cualquiera me valdría. Confieso que cuando vi los primeros dibujos, ni siquiera eran fotos, de los R20 y R30 me enamoré de ese coche. Pero no, el coche del día es el R16, un coche que cuando le vi me pareció un R6 “grandote” y que cuando lo probé me enamoró… un TX tendría, sin duda, en mi garaje.

Patrick Chirac, son célèbre maillot de bain et sa R21 tunée (Franck Dubosc dans Camping), nous l'avons tous en tête ! Surement plus cliché qu'autre chose, le camping est beaucoup plus que cela ! Dans l'industrie du tourisme, le camping est un secteur en pleine croissance. Les vacanciers ont de plus en plus tendance à opter pour des séjours en camping, que ce soit dans des tentes, des caravanes ou des mobil-homes. En France, les campings offrent une grande diversité de services et d'activités, allant des piscines et des terrains de jeux pour enfants aux espaces de détente et de loisirs pour les adultes. Les campings sont également de plus en plus soucieux de l'environnement et proposent des options de camping écologique pour les visiteurs. Ils attirent une clientèle variée, allant des familles aux groupes d'amis en passant par les personnes âgées. C'est un marché en constante évolution et il s'adapte de plus en plus aux besoins de ses clients, avec des options de location de mobil-homes de luxe, des emplacements pour les camping-cars et des offres de séjours à thème. Pour en parler aujourd'hui, j'ai le plaisir de recevoir Jérôme Mercier, le patron de Campings.com. Campings.com est le leader européen de la réservation d'hébergements de plein air sur internet. Alliant tourisme et technologie, le groupe est devenu le spécialiste du camping avec plus de 3500 établissements référencés dans 7 pays, allant du non classé au complexe 5*. Il y a quelques jours Campings.com a annoncé une levée de fonds de 27M€ et l'acquisition de son principal concurrent néerlandais ! Comme à notre  habitude, nous parlons du marché, celui de la France mais également celui des autres pays européens. L'idée est de bien comprendre l'organisation de l'offre et de la demande. Nous poursuivons notre conversation par la proposition de valeur de Campings.com. C'est à dire comment l'entreprise s'est elle développée (On ne devient pas leader européen en un clic) ? Quelle est sa singularité ? Comment se passe la croissance externe ? Et quels sont ses plans de croissance les prochaines années ? Enfin, nous finissons par les sujets de la relation client où nous parlons data, CRM, acquisition, fidélisation, réseau sociaux. Bonne écoute, toujours sans coupure !!

Notre invitée est la Dr Corine Karema, directrice générale par intérim de « Roll Back Malaria », le partenariat pour en finir avec le paludisme, qui regroupe les organisations internationales, le Fonds mondial, les bailleurs, le secteur privé et les États où sévit le parasite, en tout 500 partenaires. Le paludisme a fait 619 000 morts en 2021 dont 96% en Afrique. C'est moins qu'en 2020, mais on est toujours au-dessus de la mortalité d'avant le Covid-19, qui a perturbé la lutte contre cette pandémie. Malgré tout, l'OMS observe que les systèmes de santé nationaux de lutte contre le paludisme ont résisté. Comment l'expliquez-vous ? C'est vrai que malgré les perturbations des services de santé, et bien sûr de lutte contre le paludisme dû au Covid-19, les pays ont vraiment fait des efforts héroïques et qui ont vraiment porté leurs fruits. Premièrement, il y a le leadership des pays, et bien sûr, c'est un partenariat robuste, que ce soient les institutions bilatérales, multilatérales, les ONG, qui ont continué à fournir des efforts. 185 millions de cas de paludisme et 997 000 décès ont été évités en 2021. Et nous avons aussi vu qu'en 2021, un grand nombre des pays sont à portée de l'élimination du paludisme, et cela continue à progresser, en Afrique, nous avons le Cap-Vert, nous avons le Botswana. L'éradication du paludisme est pourtant confrontée à de nouveaux défis. Les outils de prévention et les remèdes ne sont plus aussi efficaces, le parasite est devenu résistant… Oui, il y avait neuf pays déjà en Afrique qui ont montré qu'il y a une résistance aux insecticides qui sont les pyréthrinoïdes, qui sont les insecticides qui sont utilisés tant pour les moustiquaires imprégnées et pour les pulvérisations dans les maisons. Et il y a aussi un nouveau moustique, l'Anopheles stephensi, qui se répand dans les villes ? Le nouveau moustique stephensi qui a été vu en Asie commence à être vu dans beaucoup de pays, Djibouti, en Somalie et au Nigeria. C'est un nouveau problème et c'est pour ça que l'OMS a élaboré une directive qui permet aux pays de pouvoir contrôler ce nouveau vecteur. La recherche est-elle en bonne voie pour trouver des solutions à ces problèmes ? Oui, maintenant, nous sommes à un niveau où on a vraiment un grand arsenal, des outils d'innovation qui sont en cours de développement et qui viennent d'être développés. Par exemple, quand on regarde pour les moustiquaires, on a des moustiquaires de nouvelle génération, des moustiquaires PBO, donc on ajoute à notre produit aux insecticides qui sont disponibles, pour essayer de booster l'efficacité de l'insecticide et bien sûr agresser les problèmes des moustiques qui sont résistants au pyréthrinoïde. Et du côté des médicaments et des vaccins ? En ce qui concerne les médicaments, pour le moment, il y a des nouvelles molécules qui ne sont pas à base d'artémisinine, qui sont en développement. Vous savez qu'il y a un premier vaccin qui a été approuvé par l'Organisation mondiale de la Santé (OMS) et qui est déjà mis en œuvre dans trois pays en Afrique : le Kenya, le Ghana et le Malawi, et il y a à peu près 27 pays africains qui ont déposé leur soumission à Gavi [l'Alliance mondiale pour les vaccins et la vaccination, NDLR], pour être candidat aux sites qui vont recevoir ces vaccins. Il y a aussi un nouveau vaccin qui est le R21 qui est en troisième phase d'essai clinique. Il y a aussi d'autres vaccins qui sont en développement. Il y a aussi des anti-monoclonaux qui sont aussi des outils de prévention qui pourront être des candidats de chimio prévention pour la lutte contre le paludisme. C'est pourquoi, je suis optimiste, ce sont des outils qui vont nous permettre d'éradiquer le paludisme. Le déploiement de tous ces nouveaux outils contre le paludisme va demander de l'argent. L'OMS évalue les besoins à 7,8 milliards de dollars par an et les financements, même s'ils ont augmenté en 2021, sont deux fois moins élevés que cela. Là aussi, vous êtes optimiste ? Nous venons d'avoir en septembre la conférence pour la reconstitution du Fonds mondial, de lutte contre le VIH, la tuberculose et le paludisme. Je pense que c'est une belle réussite, surtout en se situant sur le contexte présent du Covid-19, de l'impact socioéconomique, de la guerre avec l'Ukraine, le changement climatique, parce que c'est la première fois que le Fonds mondial a pu mobiliser 15 milliards de dollars. Le Fonds mondial est un partenaire très important dans la lutte contre le paludisme, maintenant avec le Covid-19, les coûts des interventions de lutte contre le paludisme ont augmenté, les coûts d'approvisionnement ont augmenté. Donc ça dépendra aussi des pas endémiques, troisième contributeur le plus important, les soins de santé primaire. ►À lire aussi : Paludisme: la situation se stabilise, mais de nouveaux risques émergent, selon l'OMS

Darren, Keri and Sky starts the show with good reminder that Quick Quiz is at R21 000 this Monday. #DarrenKeriSkyOnECR

En 2020, la crise de la Covid-19 a mis en évidence la forte dépendance de l'Afrique en matière d'approvisionnement des produits pharmaceutiques. Comment structurer une filière industrielle du médicament et du vaccin, et passer de consommateur à producteur ? Et la recherche africaine dans tout ça, où en est-elle ? Comment l'Agence africaine du médicament et les gouvernants peuvent-ils accompagner scientifiques et industriels ? Quand l'Afrique pourra-t-elle soigner les Africains ? Avec la participation de : - Dr Ndao, directrice générale de l'Agence sénégalaise de réglementation pharmaceutique - Michel Sidibé, envoyé spécial de l'Union africaine pour l'Agence africaine du médicament (AMA), ancien ministre de la Santé et des Affaires sociales de la République du Mali et ancien directeur exécutif de l'ONUSIDA - Pr Halidou Tinto, directeur de Recherche en Parasitologie et enseignant associé à l'Université Nazi Boni de Bobo-Dioulasso, directeur régional de l'Institut de Recherche en Sciences de la Santé (IRSS), investigateur principal du projet d'essai vaccinal sur le candidat vaccin contre le paludisme R21.

  Dr Richard Friedland, CEO at Netcare, on what aided it to record a 3% increase in normalised revenue to R21.6 billion for the year.      Donald MacKay, director at XA Global Trade Advisors on whether the government made the right decision to halt metal scrap exports.      Then Alan Knott-Craig Jnr, former iBurst and Mxit CEO and current Chairman at Isizwe.com spoke about his relationship with money. Knott-Craig Jnr also gave entrepreneurship lessons he learned throughout the years. See omnystudio.com/listener for privacy information.

En 2020, la crise de la Covid-19 a mis en évidence la forte dépendance de l'Afrique en matière d'approvisionnement des produits pharmaceutiques. Comment structurer une filière industrielle du médicament et du vaccin et passer de consommateur à producteur ? Et la recherche africaine dans tout ça, où en est-elle ? Comment l'Agence africaine du médicament et les gouvernants peuvent-ils accompagner scientifiques et industriels ? Quand l'Afrique pourra-t-elle soigner les Africains ?   Avec la participation de : Dr Oumy Ndao, directrice générale de l'Agence sénégalaise de réglementation pharmaceutique Michel Sidibé, envoyé spécial de l'Union africaine pour l'Agence africaine du médicament (AMA), ancien ministre de la Santé et des Affaires sociales de la République du Mali et ancien directeur exécutif de l'ONUSIDA Pr Halidou Tinto, directeur de Recherche en Parasitologie et enseignant associé à l'Université Nazi Boni de Bobo-Dioulasso, directeur régional de l'Institut de Recherche en Sciences de la Santé (IRSS), investigateur principal du projet d'essai vaccinal sur le candidat vaccin contre le paludisme R21.

This is Toby Sumpter with your CrossPolitic News Brief for Monday, January 6th, 2020. That Star Wars Lesbian Smooth NBC News reported on December 26th that authorities in Singapore and the United Arab Emirates cut the brief homosexual kiss in the latest Star Wars: The Rise of Skywalker. Singaporean authorities told the BBC that the kissing scene was cut in order to give it the PG-13 rating. Otherwise, Singapore only allows films with homosexuality by rating them R21, which prohibits anyone under the age of 21 to see it in theaters. This is because at the age of 21, young people magically become immune to corroding effects of perversion. O wait, nevermind.  The NBC News article notes that male homosexual acts are still illegal in Singapore, even though this “British colonial era law” is no longer enforced. The article notes that female homosexual acts are however, legal. While this seems a bit schizophrenic on the surface, it is striking that in the old testament law, only male homosexuality was criminalized. While Paul clearly identifies both male and female forms of homosexuality as sin in Romans 1, one of the most important distinctions Christians need to remember is the difference between sins and crimes. Only crimes are the jurisdiction of the civil magistrate. If God has not identified something as a crime in His word, it should not be a crime in our country, including things like smoking a cigar when you're 17 or wearing seatbelts. Of course either one of those things might be foolish or sinful (if you're disobeying your mother, for example), but neither should be crimes. And you cannot defend tyranny by appealing to Romans 13 or 1 Peter 2. Yes, we are to submit to human ordinances, but that doesn't remove the fact that the civil magistrate is acting tyrannically and unlawfully.  But back to that Star Wars lesbian smooch, NBC reports that Chinese authorities did not cut it. Could this indicate that they have are easing up on censoring homosexual and trans film representation? China had banned “Brokeback Mountain” few years ago and “Call Me By Your Name,” but while it granted ”Bohemian Rhapsody” a full theatrical release — it only did so with cuts of suggestive and gay content. It's striking that on this particular point the tyrannical communist regime has more decency that the United States of America.  And this links up with the recent pornography debate. Should pornography be illegal? Yes, of course. This is because pornography is a species of prostitution, and prostitution is prohibited in Lev. 19:29, Dt. 23:17, and the punishment for a priest's daughter who turned prostitute was death (Lev. 21:9). While the death penalty would be a maximum penalty in cases of extreme debauchery and corrupt, the biblical law clearly requires civil magistrates to suppress all forms of prostitution. And we should not miss the fact that prostitution has always been closely associate with idolatry. But sexual morality and the God/gods you worship always have social and political results. You are asking for a particular kind of society by how you live sexually and how you worship. It's also the other way around: the laws you enact are also asking for a certain sexuality and religion long term.  So for example, back in August, Disney's live action Mulan reboot was in the news when the lead actress Crystal Yifei Liu tweeted support for the Hong Kong police who have used increasingly harsh tactics to contain and suppress protesters. Variety's Rebecca Davis noted then that China's government widely praised the film, “putting Disney in an awkward position of having its interests defended by the world's biggest authoritarian regime.” The same article notes that Variety was able to identify scores of active accounts on Twitter that had all the hallmarks of being state-backed bots, all posting under the hashtag #supportmulan. Mulan is of course the story of the female-warrior hero, which is its own form of prostitution. A cursory glance at Twitter a few days ago, brought up mostly fan tweets for the young actress, but also still some recent commentary on the ongoing Hong Kong protests, clearly supporting the harsh tactics of the Hong Kong police. As I was preparing this news brief, I had also come across reports that Canadian public broadcasting television had made its own censorship decision this holiday season by cutting President Donald Trump's brief cameo appearance in the 1992 film Home Alone 2: Lost in New York. However, on further investigation, it appears that the cut was a routine television-time edit made back in 2014. So maybe conservatives are a little jumpy, but if the Simpson's were able to predict Trump becoming president back in 2000, maybe the Canadian's were already gearing up.  Anyway, the point here is that censorship is inevitable. It is not whether you will have censorship but what standard will be used. Could a pro-life ad be run during the SuperBowl? Let's say money is no problem, would it be allowed? Of course not. But will there be an ad with a homosexual couple in it? Almost certainly. Will there be ads with bikini babes? Of course. But could we run an ad defending the sanctity of heterosexual marriage? Not on your life. But we had already agreed to homosexuality and bestiality and prostitution when we struck down public obscenity laws. When we said we would allow prostitution on the screen, so long as someone was a certain arbitrary age, in principle we rejected God's law, rejected God, and we were turning to idols, and one of the most hideous idols was the god-state. If the State can rule against God's law, the State is claiming to be god. And you cannot do that without inevitably ultimately censoring Christians and Christian morality because Christian morality fundamentally denies the state's ultimate sovereignty and deity. Christian morality insists that the state has a legitimate but extremely limited jurisdiction under the God's law. But that's like telling an obese man he can only have a certain number of calories a day. It kind of cramps his style. So of course Christians and Christianity are currently being censored in America. Now, on the one hand, businesses should be free to accept whatever advertising they want (within biblical limits) and reject any they don't want. But we shouldn't pretend that there's an equal weights and measures going on. Everyone knows that if Toyota or Nike ran an ad celebrating motherhood and homemaking, they would be bombed into the next century by liberal extremists.  Meanwhile, all western audiences will be subjected to the Star Wars kiss. Of course you don't have to see it. You don't have to go to the movies. You don't have to fork over your money to see JJ Abrams put his two-second virtue signal pinch of incense on the altar of sexual idolatry. But then again, I'm also rather pleased that it still seems rather embarrassing. Why not go all in? Why not have a main character that's trans or flaming homosexual? Because the movie franchise would flop, tank, and disappear. Hollywood is a discipling America, and they understand the power of incrementalism. For my money, women have been known to kiss one another for centuries. We all know what they were trying to do, but I'd rather just say on that planet that's how all the godly women greet one another or express extreme relief and sisterly love. There have been human cultures that routinely greeted one another with kisses; we need not eroticize a kiss. To those who are impure, everything is impure, but to those who are pure, much remains pure. Sorry, JJ, no sexual perversion points will be awarded to you, you patriarchal pig. Now, Disney, on the other hand, your Mulan remake is an abomination, and unfortunately, far too many Christians will thoughtlessly eat that up.  North Korean Dictator Announces End to Nuclear Moratorium Lastly, and just briefly, you should be aware that on New Year's Day, North Korea's Dictator Kim Jong-Un announced that his country no longer feels bound by its self-imposed moratorium on testing nuclear weapons and long-range ballistic missiles. Mr. Kim said that the testing of new weapons would be witnessed by the world in the near future. It is believed that North Korea has not tested any long range missiles or nuclear weapons in over two years.  Recall that President Trump has met with Mr. Kim three times during his presidency, and Trump has repeatedly insisted that he has a good relationship with the Communist Dictator, even as recently as last Tuesday. But North Korea had set December 31 as a deadline asking the United States to make some concessions to the heavy sanctions that remain against North Korea for their various human rights abuses, and with no concessions made, Mr. Kim told his party that his country will shift to a “shocking actual action” that will make the United States “pay for the pains sustained by our people.” Mr. Kim called the US treatment of North Korea “gangster-like acts” and called on the people of North Korea to “foil the enemies' sanctions.” The New York Times' Choe Sang-Hun reports that while North Korea has demonstrated that its fleet of missiles could likely reach parts of the United States, it is not clear that the country has a nuclear warhead that could survive re-entry into the earth's atmosphere. While there are no doubt many complexities here, one note of interest is the government run media funneling the exact information to the people of North Korea that the North Korean dictator wants. So here we return to the notion of censorship and media, and culture war. Christians are people of the word because we worship the Word made flesh. And that Word has dwelt among us, and we have beheld his glory. That Word has also spoken through the patriarchs and prophets and apostles, and we have that Word preserved for all time in the Bible. The Bible is God's Word. It is God's truth. And it is the truth that sets all men free. This freedom is political, economic, and social, as well as spiritual.  The world is an insanely complex place, and it can be hard to know what to think. But the Word of God is available to us. You probably have a number of copies all around your house. Are you reading? Are you listening? Are you marinating? The Word of God is a light. Do you need light? The Word of God is a sword. Do you need to address sins in your life or your family? The word of God is also a strong tower, a defense. We have a power that Kim Jong Un cannot imagine. Actually, given the fact that Bibles are illegal in North Korea, I suspect that he does imagine. And if Trump really wanted to set off a reaction, that's where he would push. Let the Bibles in. And same thing goes for Saudi Arabia and Iran and China. Well, quite frankly, we need a massive revival of Bible reading and Bible preaching in the West. Reading certain verses out loud in public would get you arrested in many places in our so-called “free” countries.   Speaking of Bible reading, if you're looking for a new Bible reading plan for the new year, you're most welcome to join the Christ Church Bible Reading Challenge. Our plan runs September through May, but there are facebook pages for men and women and you are most welcome to jump in at any time. Go to www.christkirk.com/biblechallenge to find out more.  If you or someone you know is looking for a rigorous Christian college, I would also suggest you check at New St. Andrews College, a liberal arts college for leaders who want to shape culture under the Lordship of Jesus Christ. Find out more at www.nsa.edu. You can find this show and all of the other shows at fightlaughfeast.com. If you enjoyed this please share it with your friends, and if you'd like to see us doing more of this sort of thing. You can become a supporting member by going to flfnetwork.com/membership. Have a great day.

This week we talk about quinine, the R21 vaccine, and Anopheles.We also discuss mosquitoes, repellents, and the World Health Organization. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe